OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
March 14, 2024
Webinar Date/Time: Wed, Apr 24, 2024 11:00 AM EDT
March 08, 2024
EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.
March 07, 2024
Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.
Webinar Date/Time: Tue, Mar 26, 2024 11:00 AM EDT
March 06, 2024
Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.
Webinar Date/Time: Tue, Apr 9, 2024 11:00 AM EDT
Webinar Date/Time: Friday, April 5, 2024 at 11amEDT | 10am CDT | 8am PDT
March 04, 2024
March 03, 2024
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.